JMP Securities believes the manufacturer of an atrial fibrillation device could experience a 70% increase in value.
Shares of medical device provider AtriCure are a lucrative investment opportunity, according to JMP Securities. Analyst Daniel Stauder initiated coverage of the stock with an outperform rating and a price target of $60, suggesting that the shares could increase by almost 70%. Stauder stated that AtriCure is the leading player in treating complex forms of…